132 results about "Renal tissue" patented technology

Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker set. Also disclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, method of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

The invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine compositions. In order to solve the problems that the target spot of western medicine for treating diabetic nephropathy is single, and the adverse reaction risk is large when multiple medicines are combined for use, the invention provides a traditional Chinese medicine composition for treating diabetic nephropathy, and the traditional Chinese medicine composition comprises white ginseng, astragalus membranaceus, scorched atractylodes macrocephala, poria cocos, endothelium corneum gigeriae galli, kudzu vine root, medlar, Chinese yam, dogwood and rhizoma alismatis. The traditional Chinese medicine composition has the advantages of multiple components, multiple targets and small adverse reaction, animal experiments prove that the traditional Chinese medicine composition provided by the invention can remarkably improve the levels of blood sugar, blood fat, urine protein, creatinine and urea nitrogen of rats, can remarkably improve pathological changes of renal tissues of model rats, can specifically increase the activity of SIRT1 and PGC-1alpha, and can be used for treating the renal diseases of the rats. The traditional Chinese medicine composition can be used for treating diabetic nephropathy, correcting the metabolic pathway of podocyte and recovering the mitochondrial function, is an effective medicament for treating diabetic nephropathy, and provides a new pathway for clinical multi-target treatment of diabetic nephropathy.

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

The invention belongs to the technical field of medicines, and particularly discloses a biomarker for detecting kidney fibrosis related diseases and application of the biomarker. The biomarker comprises serum copper cyanin, or the serum copper cyanin and serum creatinine. Compared with other methods for diagnosing renal fibrosis, the serum cupreuloplasmin has the following three advantages: 1, compared with a conventional diagnostic marker (such as serum creatinine), the cupreuloplasmin can detect up-regulation in the serum of a patient suffering from early chronic kidney diseases, and can be combined with an existing mature diagnostic marker for detection; secondly, compared with renal tissue pathologic biopsy, the use of the copper cyanin as the diagnostic marker has non-invasiveness, and only a small amount or even a trace amount of patient serum is needed, so that the harm to the body health of the patient is avoided; and thirdly, compared with a nuclear magnetic resonance method for analyzing the metabolic components of the urine, the method for detecting the markers in the serum is lower in cost, more flexible, high in timeliness and easier to popularize.

Apparatus, systems, and methods provide access to the renal pelvis of a kidney to treat renal nerves embedded in tissue surrounding the renal pelvis. Access to the renal pelvis may be via the urinary tract or via minimally invasive incisions through the abdomen and kidney tissue. Treatment is effected by exchanging energy, typically delivering heat or extracting heat through a wall of the renal pelvis, or by delivering active substances to ablate a thin layer of tissue lining at least a portion of the renal pelvis to disrupt renal nerves within the tissue lining of the renal pelvis.

The invention belongs to the technical field of biological medicine, and particularly relates to an in-vitro fusion technology for multi-lineage human kidney organs and application thereof. The invention provides a method for realizing culture of multilineage kidney organs by fusing kidney units and ureteral bud organs in vitro. According to the in-vitro fusion technology of the kidney organoid reported by the invention, two organoid with different pedigree sources, namely the kidney unit and the ureteral bud, can be efficiently fused, a UB tubular structure is integrated into the kidney unit organoid, and the UB tubular structure starts from a single ureteral bud and is wrapped by kidney unit precursor cells in a similar in-vivo development process, and finally develops into a kidney with glomerulus and a plurality of kidney cells. The multi-lineage renal organ comprises a catheter, a proximal tube, a marrow tab thin section, a distal tube, a connecting tube and a ureteral bud with a single outlet. A framework is provided for an engineered renal unit and a smooth collection system, and the method is an important step for generating the functional renal tissue from the beginning.

The application discloses a marker for determining the severity of IgAN kidney tissue lesions and application thereof, and inventors find that ACTN4, ACADS and COL1A1 are significantly differentially expressed proteins in kidney tissues. The significant down-regulation of ACTN4 may cause the change of actin cytoskeleton of IgAN glomerular podocytes; the significant down-regulation of ACAD may indirectly participate in the occurrence process of abnormal structure and function of IgAN renal tubular epithelial cells by affecting fatty acid metabolism in the cells; and the significant up-regulation of COL1A1 may participate in the accumulation of extracellular matrix in the renal interstitium of IgAN, and play a certain role in promoting the renal interstitial fibrosis. The combination of ACTN4, ACADS and COL1A1 has good prediction efficiency for the diagnosis of the severity of IgAN kidney tissue lesions, and the area under the ROC curve is 0.815, P 0.043. In addition, the immunohistochemical results also confirm the expression trend of the three proteins ACTN4, ACADS and COL1A1 in the corresponding kidney tissue substructures in proteomics.

This invention provides the application of dehydrouncitonin in the preparation of drugs that reduce polymyxin toxicity, belonging to the field of pharmaceutical technology. This invention uses dehydrouncitonin in combination with polymyxin. The combined use of dehydrouncitonin and polymyxin E increased the viability of HEK293T and RAW264.7 cells to 87.7% and 94.3%, respectively, with highly significant differences compared to the control, indicating that treatment with dehydrouncitonin in combination with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E. This invention uses a mouse model to demonstrate that treatment with dehydrouncitonin in combination with polymyxin E can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone in mice, specifically manifested in improved neurobehavioral effects and improved histopathological effects on brain and kidney tissues. This invention uses dehydrouncitonin in combination with polymyxin E to significantly inhibit the cytotoxic, neurotoxic, and nephrotoxic effects of polymyxin E.

The invention discloses a novel application of elsholtzia rugulosa extract in preparation of a medicine for preventing and treating acute kidney injury, and belongs to the technical field of biology. The medicine is applied to prevention and / or treatment of acute kidney injury, the content of urea nitrogen (BUN) in plasma can be reduced, pathological injury of kidney tissue is improved, and expression of related factors in the kidney tissue is adjusted; the elsholtzia rugulosa extract can effectively reduce the content of BUN in plasma of a cis-platinum (CDDP)-induced acute kidney injury model mouse, effectively improve pathological injury of kidney tissue of the cis-platinum-induced acute kidney injury model mouse and regulate expression of related factors in the kidney tissue of the cis-platinum-induced acute kidney injury model mouse under a relatively low dosage. The raw materials come from natural products and are convenient to collect and high in safety.

The application relates to an application of a drug for preventing and treating deafness in preparation of a drug for preventing and treating acute kidney injury caused by cisplatin, wherein the effective component of the drug for preventing and treating acute kidney injury caused by cisplatin is prepared from raw medicinal materials in the following weight percentage: 27-33% of ginseng, 16-20% of astragalus, 16-20% of pueraria, 11-13% of curcuma, 12-15% of platycodon, and 8-10% of licorice. The drug for preventing and treating acute kidney injury caused by cisplatin in the application can obviously reduce the creatinine and urea nitrogen levels, improve the morphological damage of kidney tissues, and has a remarkable effect on preventing and treating acute kidney injury caused by cisplatin.

The invention belongs to the technical field of biological medicines, and particularly relates to a traditional Chinese medicine composition for treating chronic renal failure of pets and a liposome and application thereof. According to the traditional Chinese medicine composition provided by the invention, by virtue of turmeric, eucommia ulmoides, medlar, astragalus membranaceus, poria cocos and beta-sitosterol, the aim of synergistically treating the renal failure in the aspects of resisting inflammation, inhibiting renal fibrosis, improving a glomerular filtration function, promoting kidney cell repair and the like can be achieved, and a new solution is provided for effectively treating the chronic renal failure of pets. The traditional Chinese medicine composition disclosed by the invention has a good recovery effect on kidney tissues of pets with chronic renal failure, can effectively reduce urea nitrogen and creatinine levels of blood of the pets with chronic renal failure, relieves renal failure symptoms, and has a good treatment effect; the liposome disclosed by the invention has the advantages of high effective rate, high cure rate and quick effect, and the treatment effect of the liposome is superior to that of a third-stage clinical medicine, namely beraprost, for treating the kidney renal failure of pets in the current market.

The invention discloses an application of PARP1PROTACA19 in preparation of a medicine for preventing and treating acute kidney injury, and relates to the technical field of medicines, and the key points of the technical scheme are as follows: PARP1PROTAC A19 can reduce the expression level of PARP1 in HK2 cells and mice, reduce the levels of acute kidney injury markers KIM-1 and inflammatory factors of the HK2 cells and the mice, improve pathological changes of kidney tissues, and inhibit the occurrence of acute kidney injury. The traditional Chinese medicine composition has obvious prevention and treatment effects on acute kidney injury.

The invention provides a traditional Chinese medicine composition and application, and relates to the technical field of medical biologica.In the embodiment of the invention, the treatment effect of the traditional Chinese medicine composition comprising radix astragali, radix et rhizoma rhei, leech, radix salviae miltiorrhizae and herba epimedii on DN model rats is studied through transcriptome sequencing. The rat models are divided into a control group, a DN group and a treatment group. Creatinine (Cr), blood urea nitrogen (BUN), and urinary albumin levels of each group are measured. And the pathological change of the kidney tissue is observed by adopting Masson dyeing and PAS dyeing. The result shows that compared with the DN group, the Cr, BUN and urinary albumin levels of the treatment group are obviously reduced (plt; 0.05) of the method. And the masson dyeing shows that the kidney collagen fibers in the treatment group are reduced. In addition, PAS staining shows that the mesangial expansion of the treatment group is less, and the extracellular matrix deposition is reduced. It is indicated that the composition can effectively reduce the Cr, BUN and urinary albumin levels of DN rats, and has a certain degree of kidney protection effect.

The invention discloses a diabetic nephropathy marker PARP1, a primer combination and application, and relates to the technical field of biology. The sequence of the primer combination is PARP1-F, and is as shown in SEQ ID NO. 1; 1, PARP1-R as shown in SEQ ID NO. 2; an internal reference primer beta-actin-F, which is as shown in SEQ ID NO. 17; an internal reference primer beta-actin-R is as shown in SEQ ID NO. 18. The invention finds that the expression of PARP1 in the kidney tissue of a patient with diabetic nephropathy is increased and is positively correlated with ACR (Activated Receptor). The invention also finds that PARP1 is related to podocyte damage, and knocking down PARP1 can relieve podocyte endoplasmic reticulum stress and apoptosis, and can reflect the progress of DKD to a certain extent.

The application discloses a biomarker for diagnosing diabetic nephropathy and application thereof, and relates to the technical field of biological medicine. The biomarker for diagnosing diabetic nephropathy comprises urine MBP-1 or urine MBP-1 / urine creatinine. The urine MBP-1 or urine MBP-1 / urine creatinine biomarker has high identification efficiency: when the urine MBP-1 or urine MBP-1 / urine creatinine ratio is used for identifying DKD and NDRD, the area under the ROC curve (AUC) reaches 0.899, the sensitivity and the specificity are both higher than 0.85, and the two diseases can be efficiently distinguished. The method is non-invasive and convenient: only urine samples need to be collected, the risk of complications such as bleeding and infection caused by invasive operations such as kidney biopsy is avoided, the patient has high acceptance, repeated detection can be performed to dynamically track the disease condition, and special equipment is not needed, so that the method is convenient for clinical popularization and application. Through kidney tissue immunofluorescence verification, MBP-1 is deposited in a large amount in the glomerulus of DKD and is not deposited in NDRD, and thus the kidney local pathological change can be directly reflected.

The application belongs to the field of biological medicine, and provides application of miR-152 as a target in preparation of a drug for treating podocytopathy and the drug. Specifically, the application relates to application of miR-152 as a therapeutic target and / or a drug screening target in preparation of a drug for treating podocytopathy and a drug for treating FSGS nephropathy. The miR-152 inhibitor can inhibit high expression of miR-152 in kidney tissues of podocytopathy or FSGS nephropathy, inhibit down-regulation of synaptopodin protein, RhoA protein and 14-3-3 beta protein expression, protect stability of a cytoskeleton of a podocyte in kidney tissues, and delay progressive development of FSGS disease. The application provides a new therapeutic target for treatment of FSGS disease, and has important social and economic significance.

The present invention belongs to the field of biomedical technology and specifically discloses the use of a substance that inhibits the activity and / or expression of a CAPG gene or protein in preparing a product for treating renal fibrosis caused by renal injury. The present invention first discovered through research that CAPG is expressed at a low level in normal renal tissue, but its expression level is elevated in renal tissue of patients with acute renal injury, minimal change disease, IgA nephropathy, lupus nephritis, and diabetic nephropathy, indicating that CAPG expression may be involved in the occurrence and development of renal fibrosis caused by renal injury. Then, by constructing a CAPG knockout mouse model, it was found that knocking out CAPG can effectively reduce the progression of renal fibrosis. By culturing renal fibroblasts in vitro, it was found that silencing or knocking down CAPG can inhibit TGF-β-induced renal fibroblast activation. The research of the present invention is of great significance for the pathogenesis and treatment of renal injury or renal fibrosis.

A compound for inhibiting C3 gene expression, a pharmaceutical composition and a use thereof, belonging to the technical field of small nucleic acid drug delivery. A compound conjugated with an oligonucleotide and a pharmaceutical composition thereof can significantly inhibit the expression of C3 mRNA in animal liver tissue and C3 protein in serum and can reduce C3 deposition in renal tissue and improve the course of disease featuring C3 deposition in renal tissue. The no-adverse-effect level (NOAEL) in SD rats and cynomolgus monkeys is 300 mg / kg. The compound conjugated with a oligonucleotide and the pharmaceutical composition thereof are helpful in alleviating, preventing and / or treating diseases or conditions mediated by dysregulated C3 gene expression.

The present invention relates to a traditional Chinese medicine composition for treating diabetic nephropathy and a preparation method thereof, belonging to the technical field of traditional Chinese medicine compositions. To solve the problems of single target for western medicine in treating diabetic nephropathy and high risk of adverse reactions when using a combination of multiple drugs, the present invention provides a traditional Chinese medicine composition for treating diabetic nephropathy. The composition formula includes white ginseng, astragalus membranaceus, stir-fried atractylodes macrocephala, poria cocos, chicken gizzard-membrane, kudzu root, wolfberry fruit, Chinese yam, cornel fruit and oriental waterplantain rhizome. The traditional Chinese medicine composition of the present invention has the advantages of multiple components and multiple targets and small adverse reactions. Animal experiments prove that the traditional Chinese medicine composition provided by the present invention can significantly improve the blood glucose, blood lipid, urine protein, creatinine and blood urea nitrogen levels of rats, can significantly improve the pathological changes of the renal tissue of model rats, and can correct the podocyte metabolic pathway and restore its mitochondrial function by specifically increasing the activities of SIRT1 and PGC-1α. It is an effective medicine for treating diabetic nephropathy and provides a new way for the multi-target treatment of clinical diabetic nephropathy.

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

Provided are a kidney-targeting delivery ligand, a conjugate, a composition, and a use thereof, relating to the technical field of oligonucleotide drugs. Provided is a delivery ligand suitable for kidney targeting. The delivery ligand and an active substance (such as an oligonucleotide) are covalently linked by means of a linker group to obtain an oligonucleotide conjugate. The oligonucleotide conjugate has affinity for a cell receptor present on a kidney target cell and can selectively and effectively reduce or inhibit the expression of a kidney target gene in a subject (such as human or animal). The provided oligonucleotide conjugate or pharmaceutical composition can effectively treat and / or prevent pathological conditions or diseases caused by aberrant expression of a specific gene in kidney tissue cells.

The present invention provides a blood sugar lowering inulin fermentation product and its preparation and application, belonging to the field of microbial fermentation technology. The blood sugar lowering inulin fermentation product is obtained by fermenting inulin with a specific fermentation bacterium, Schleiferilactobacillus harbinensis JNDM, which has been deposited in the Guangdong Provincial Microbiological Culture Collection Center on December 11, 2023, with a deposit number of GDMCC No. 64143. The inulin fermentation product can significantly enhance the blood sugar lowering effect of inulin, reduce complications of hyperglycemia, improve anti-inflammatory function, and effectively relieve pancreatic and renal tissue lesions; it can regulate the homeostasis of intestinal flora, and significantly increase the diversity of intestinal microorganisms and the content of beneficial metabolites in the intestine. It can be used as a food, health product, medicine or functional beverage for preventing and treating type 2 diabetes and its complications or for lowering blood sugar.

The invention provides application of trigonelline in preparation of a medicine for treating sepsis, and belongs to the technical field of biological medicine. The invention develops a novel medicine, namely the trigonelline for treating sepsis, the treatment effect of the trigonelline on sepsis is detected, and the result proves that the treatment of the trigonelline can inhibit kidney tissue injury caused by sepsis and reduce the expression of inflammatory factors. The natural chemical component trigonelline extracted from plants is used for treating sepsis injury, the safety is high, the treatment effect is good, a new effective treatment medicine is provided for treatment of sepsis, and the problem that an effective sepsis prevention and treatment medicine is lacked clinically is solved.

The invention discloses a 15-antibody combination for accurately detecting a mouse tissue immune cell subset and application of the 15-antibody combination. Aiming at the problems of large fluctuation and instability of detection results caused by adjustment of voltage and fluorescence compensation during detection by a flow cytometer and different processing modes during result analysis, the antibody combination disclosed by the invention takes monoclonal antibodies CD45, CD3, CD4, CD8, CD19, B220, Ly-6C, Ly-6G, MHC-II, CD11c, CD49b, CD62L, CD44 +, PD-1 and PD-L1 as effective components, and a stable and standard detection method for mouse tissue immune cell subsets is established. The method can analyze the proportion, number and distribution of various immune cells (T cells, B cells, NK cells, dendritic cells, mononuclear cells and granulocytes) in spleen, lung, liver, brain or kidney tissues of mice, can reflect the immune state of the mice and evaluate the immunosuppression state, and can be applied to the fields of disease models, drug evaluation, vaccine development and the like.

The invention relates to an application of a succinate dehydrogenase subunit SDHC protein and a coding gene thereof in preparation of a medicine for preventing and / or treating renal fibrosis, and belongs to the field of biological medicines. The invention proposes and verifies that SDHC gene delivery can alleviate kidney pathological changes of chronic kidney diseases for the first time; the expression level of kidney tissue fibrosis related indexes is reduced; the transdifferentiation of renal tubular epithelial cells to myofibroblasts is inhibited. SDHC gene delivery can achieve the effect of improving the chronic kidney disease, and good development and application prospects are achieved.

The invention relates to the technical field of surgical planning, in particular to a kidney tumor accurate resection path planning method and system based on three-dimensional modeling, and the method comprises the following steps: obtaining a kidney tissue tumor surface area, extracting a line segment towards a renal gate direction, extending a direction vector, constructing a passing guide line, and continuing a path to a compression direction; extracting a blood vessel crossing path section, dividing an interference area, adjusting the direction of a turning section, connecting a tumor and a renal gate, and generating a resection path planning result set. According to the method, by constructing a direction line segment set extending along a structure compression trend, advancing a path space trend segment by segment, combining a replacement mechanism of regions with inconsistent directions, depending on density division of crossing edge point segments, defining the distribution position of a traffic limited region, adjusting repeated turning segments through direction lines, and eliminating path fluctuation and turn-back interference, the traffic limited region is determined. The extending direction penetrates through the tumor center and is connected with the starting point path, the path track integrally keeps smooth extension, the space layout is more ordered, and the matching performance of the passing line segment structure is enhanced.

The invention discloses a renal interstitial fibrosis noninvasive grading model construction method and system based on multi-parameter MRI, and belongs to the technical field of medical image processing and artificial intelligence, and the method comprises the steps: S1, collecting multi-parameter MRI data of a renal interstitial fibrosis patient and a healthy contrast; s2, preprocessing the data; s3, performing cortex and medullary segmentation on the preprocessed data, and extracting features of the kidney tissue after segmentation; s4, fusing the extracted features, and constructing a comprehensive feature vector; s5, taking the fused comprehensive feature vector and a corresponding renal tissue pathological grading result as training data, inputting the training data into a deep learning model for training, and establishing a non-invasive grading model related to pathological grading; according to the multi-parameter MRI-based renal interstitial fibrosis non-invasive grading model construction method and system provided by the invention, non-invasive and accurate evaluation of the degree of renal interstitial fibrosis is realized by integrating multi-parameter MRI data and a machine learning algorithm.

This document provides methods and materials involved in identifying and treating mammals (e.g., humans) having membranous nephropathy. For example, methods and materials for detecting the presence of autoantibodies specific for an EXT1 and / or EXT2 polypeptide as well as methods and materials for detecting the presence of kidney tissue having an elevated level of an EXT1 and / or EXT2 polypeptide are provided. In addition, methods and materials for treating membranous nephropathy by administering an immunosuppressant are provided.